Skip to main content
. 2022 Nov 17;2022(11):CD014963. doi: 10.1002/14651858.CD014963.pub2

12.2. Analysis.

12.2

Comparison 12: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days